Close menu




July 23rd, 2025 | 07:10 CEST

TAKEOVER SPECULATION! Barrick Mining, Evotec, Desert Gold

  • Mining
  • Gold
  • Biotechnology
  • Takeover
Photo credits: ChatGPT

Just like the high prices, takeover speculation in the gold sector is also continuing. Desert Gold is repeatedly mentioned as a candidate. With its exciting acquisition in West Africa, the explorer has diversified and made itself even more attractive to a large corporation. Perhaps Barrick? The heavyweight is currently focusing on its ore mines and selling smaller projects. It could then expand again in the gold sector, and Desert certainly fits in regionally. In the biotech sector, Evotec has long been rumored as a takeover candidate. Following the latest revenue warning, this is likely the only hope for investors to achieve short-term returns. Or was the price slide exaggerated?

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BARRICK MINING CORPORATION | CA06849F1080 , EVOTEC SE INH O.N. | DE0005664809 , DESERT GOLD VENTURES | CA25039N4084

Table of contents:


    Desert Gold: 2 Aces for rising prices

    When it comes to takeover candidates in the gold sector, the name Desert Gold keeps coming up. In recent weeks, the West Africa-focused explorer has made itself even more attractive to one of the major gold producers through its own acquisition. Exciting news is expected in the coming weeks. That could finally push the stock out of its sideways movement. Desert is currently trading at CAD 0.08, which corresponds to a market capitalization of around CAD 20 million. Analysts at GBC Research estimate the fair value to be CAD 0.425.

    There should be some long-awaited news about the flagship SMSZ project in Mali in the coming weeks: The Preliminary Economic Assessment (PEA) for a mine is expected. Given current gold prices, this should be extremely positive. Desert could then ramp up production within a few months and become a gold producer in 2026 – unless it is acquired before then.

    With the acquisition of 90% of the Tiegba Gold project in Côte d'Ivoire, the Company has another ace up its sleeve since this year. The country has developed into one of the most stable and investor-friendly mining regions in West Africa. As with SMSZ, Tiegba is also located in the vicinity of numerous gold companies, which are likely to keep an eye on its progress.

    Tiegba covers an area of 297 km². Only 20% of the concession area has been explored in detail so far. The potential is correspondingly great. The heart of the project is a gold-in-soil anomaly measuring 4.2 km long and 2.1 km wide. Historical samples showed 50 to over 200 ppb gold. The upcoming tests will now determine the depth of the gold deposit.

    https://youtu.be/AQKxVIqmfwQ?si=GiHQAgpnt6w4ISGf

    Barrick Mining: Focus on copper for now, but what next?

    Barrick is also a potential buyer for both Desert Gold projects. Even if the Company is currently on the selling side for a change. First, let's take a look at the stock: After a rapid rise from EUR 16 to EUR 19 within four weeks, Barrick Mining's stock has settled down somewhat. Similar to the gold price.

    However, with Barrick, one must stop looking only at the gold price. That is why the name change makes sense. The renaming of Barrick Gold to Barrick Mining underscores the realignment. Gold remains central, but copper is gaining in importance. CEO Mark Bristow aims to position the Company as a diversified metal producer in the long term, with copper as a second pillar.

    A key project on this path is Reko Diq in Pakistan, one of the world's largest undeveloped copper-gold deposits. After long delays, preparations are now underway for production to start in 2028/2029. Investments are also being made in Zambia. The Lumwana mine is to be expanded at a cost of several million USD and copper production doubled to around 240,000 tons.

    Parallel to the copper expansion, Barrick is divesting projects that no longer align with its new strategic direction. Instead of capital-efficient, high-cost mines, Barrick wants to focus on large, high-margin deposits with long-term potential. Among the candidates for sale is the Hemlo mine in Canada. The long-established gold mine has been an integral part of the North American portfolio for decades, but has been suffering from declining ore grades and rising operating costs for some time. The sale process has been officially launched and, according to Bloomberg, Discovery Silver is close to acquiring Hemlo.

    There could be news by August 11, 2025, at the latest, when Barrick will report on developments for the second quarter.

    Evotec: Revenue forecast cut

    Evotec will likely need a takeover to see rapid share price gains. This has now become clear once again. On Monday, the German biotech company's shares lost almost 17% after a revenue warning.

    Evotec announced that revenue for the current year will be between EUR 760 million and EUR 800 million. The previous forecast was EUR 840 million to EUR 880 million. Last year, revenue amounted to EUR 797 million. The Company cited lower-than-expected revenues in its core business, specifically in the Shared R&D segment, as the reason for the adjustment.

    R&D expenses are expected to be between EUR 40 million and EUR 50 million, and thus remain unchanged. This also applies to the adjusted EBITDA forecast of EUR 30 million to EUR 50 million (2024: EUR 22.6 million). The medium-term outlook has also not been adjusted. By 2028, Evotec aims to increase its annual revenue by an average of 8% to 12% and to increase its EBITDA margin to more than 20% during this period.

    Evotec CEO Dr. Christian Wojczewski: "We are on track to achieve sustainable, profitable growth. The strong demand for higher-margin business areas reflects the strength of our platforms and confirms the decisions we have made in terms of focus, partnerships, and capital efficiency. While some areas of our business continue to operate in a challenging market environment, the implementation of our "Priority Reset" and our new strategy gives us confidence that we are well positioned to achieve our long-term goals."

    Based on the announcement, the share price decline appears somewhat exaggerated. On the other hand, the low growth prospects within the new strategic direction had already been criticized in recent months.


    Barrick Mining does not appear to be interested in acquisitions at this time. The focus on large ore projects and the sale of smaller mines seems logical. There is likely to be a lot of activity at Desert Gold in the coming weeks. The Company has acquired an exciting project, and the PEA for its flagship project should pique the interest of investors and potential buyers. Against this backdrop, the stock appears undervalued. At Evotec, on the other hand, investors can probably only hope for a quick return through a takeover.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST

    Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight

    • Biotechnology
    • Biotech
    • Pharma
    • LifeSciences

    Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.

    Read

    Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST

    AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!

    • antimony
    • CriticalMetals
    • Defense
    • Biotechnology
    • Oncology
    • AI

    Created and published on behalf of Antimony Resources Corp.

    The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.

    Read

    Commented by Nico Popp on July 15th, 2026 | 08:30 CEST

    Built on Sand? Barrick Mining Under Pressure, Rio Tinto Facing Headwinds, and North Arrow Minerals in a Strong Position

    • Mining
    • Gold
    • Africa
    • Commodities
    • Diamonds
    • ironore
    • Copper

    The demand for strategic metals, the challenging geopolitical environment, and new exploration methods—these factors are prompting established corporations and smaller exploration companies to adapt their business models in the face of these multifaceted challenges. While the major producers are streamlining their portfolios, which have grown over the years and are sometimes complex, smaller companies are demonstrating agility by divesting marginal projects and focusing on promising deposits in politically stable regions. We examine these developments and highlight exciting companies.

    Read